Literature DB >> 10869450

Biliary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats.

Z Gregus1, A Gyurasics, I Csanaky.   

Abstract

In rats exposed to arsenite (AsIII) or arsenate (AsV), the biliary excretion of arsenic depends completely on availability of hepatic glutathione, suggesting that both AsIII and AsV are transported into bile in thiol-reactive trivalent forms (Gyurasics et al. [1991], Biochem. Pharmacol. 42, 465-468). To test this hypothesis, the bile and urine of bile duct-cannulated rats injected with AsIII or AsV (50 micromol/kg, iv) were collected periodically for 2 h and analyzed for arsenic metabolites by HPLC-hydride generation-atomic fluorescence spectrometry. Arsenic was excreted predominantly into bile in AsIII-injected rats, but the urine was the main route of excretion in AsV-exposed rats. Injected AsIII was excreted in urine practically unchanged, whereas both AsV and AsIII appeared in urine after administration of AsV. Irrespective of the arsenical administered, the bile contained 2 main arsenic species, namely AsIII and a hitherto unidentified metabolite. Formation of this metabolite could be prevented by pretreatment of the rats with the methylation inhibitor periodate-oxidized adenosine, indicating that it is a methylated arsenic compound. This metabolite could be converted in vitro into monomethylarsonic acid (MMAsV) by oxidation, whereas synthetic MMAsV could be converted into the unknown metabolite by reduction. Consequently, this biliary metabolite of both AsIII and AsV is monomethylarsonous acid (MMAsIII), a long-hypothesized, but never identified, intermediate in the biotransformation of AsIII and AsV. Although MMAsIII is thought to be formed from an oxidized precursor, rats injected with MMAsV did not excrete MMAsIII. In summary, the inorganic arsenicals investigated are transported into bile exclusively in trivalent forms, namely as AsIII and MMAsIII, but are excreted in urine in both tri- and pentavalent forms. Identification of MMAsIII is signified by the fact that this metabolite is more toxic than AsIII and AsV and thus formation of MMAsIII represents toxification of inorganic arsenic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869450     DOI: 10.1093/toxsci/56.1.18

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

1.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2005-10-15       Impact factor: 4.219

2.  The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.

Authors:  Milena Salerno; Maria Petroutsa; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2002-04       Impact factor: 2.945

3.  Arsenic distribution in water/sediment system of Sevojno.

Authors:  Snežana Aksentijević; Jelena Kiurski; Milica Vučinić Vasić
Journal:  Environ Monit Assess       Date:  2011-03-17       Impact factor: 2.513

4.  Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes--mechanistic insights and implications for further experiments.

Authors:  Michael R Easterling; Miroslav Styblo; Marina V Evans; Elaina M Kenyon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Sean D Conklin; John T Creed; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2007-10-22       Impact factor: 4.219

6.  Principles and application of an in vivo swine assay for the determination of arsenic bioavailability in contaminated matrices.

Authors:  Matthew Rees; Lloyd Sansom; Allan Rofe; Albert L Juhasz; Euan Smith; John Weber; Ravi Naidu; Tim Kuchel
Journal:  Environ Geochem Health       Date:  2008-12-23       Impact factor: 4.609

7.  Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies.

Authors:  Anthony Samsel; Stephanie Seneff
Journal:  Surg Neurol Int       Date:  2015-03-24

8.  Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice.

Authors:  Yaxiong Xie; Kevin J Trouba; Jie Liu; Michael P Waalkes; Dori R Germolec
Journal:  Environ Health Perspect       Date:  2004-08       Impact factor: 9.031

9.  Methylated trivalent arsenic-glutathione complexes are more stable than their arsenite analog.

Authors:  Andrew J Percy; Jürgen Gailer
Journal:  Bioinorg Chem Appl       Date:  2008       Impact factor: 7.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.